Achilles Therapeutics
$0.83
15
+$0+0.48% Friday 20:59
Statistics
Day High
-
Day Low
-
52W High
1.87
52W Low
0.74
Volume
56,133
Avg. Volume
82,386
Mkt Cap
33.85M
P/E Ratio
0
Dividend Yield
-
Dividend
-
Upcoming
Earnings
5MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.61
-0.47
-0.33
-0.19
Expected EPS
-0.19
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ACHL. It's not an investment recommendation.
Analyst Ratings
11$Average Price Target
The highest estimate is $11.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Show more...
CEO
Employees
242
Country
US
ISIN
US00449L1026
WKN
000A3CUPM